CompanyUTHRNasdaqSilver Spring, MD

United Therapeutics

United Therapeutics develops therapies for rare diseases including pulmonary arterial hypertension, and manufactures organs for transplantation.

SEC EDGAR ClinicalTrials.gov unither.com

8-KSep 30Latest SEC filing

Sep 23Latest story

September 2026

United Therapeutics: TYVASO DPI (NDA214324) SUPPL 7 approved

Sep 23Regulatory decisiontreprostinil United TherapeuticsRecord notice

United Therapeutics discloses share count for $477.6 million ASR deal with Citi

Sep 8PartnershipUnited Therapeutics

August 2026

Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal study

Aug 12Quarterly updateLiquidia Corp treprostinil

United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027

Aug 5Quarterly updateralinepag treprostinil

FDA approves manufacturing supplement for Orenitram tablets from UNITED THERAP

Aug 4Regulatory decisiontreprostinil United Therapeutics

July 2026

United Therapeutics names Victor Dzau to board of directors

Jul 23PeopleUnited Therapeutics

United Therapeutics posts results for terminated Phase 3 ralinepag CPET study

Jul 6Trial updateralinepag United Therapeutics

June 2026

United Therapeutics shareholders approve 2026 stock incentive plan at annual meeting

Jun 29PeopleUnited Therapeutics